-
公开(公告)号：US20160009696A1
公开(公告)日：2016-01-14
申请号：US14772290
申请日：2014-02-27
Applicant: Michael MILLER , Kallol BASU , Duane DEMONG , Jack SCOTT , Wei LI , Joel HARRIS , Andrew STAMFORD , Marc POIRIER , Paul TEMPEST , MERCK SHARP & DOHME CORP.
Inventor： Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Wei Li , Joel Harris , Andrew Stamford , Marc Poirier , Paul Tempest
IPC: C07D403/14 , C07D401/14 , C07D491/107 , C07D417/14 , C07D471/10 , C07D413/14 , C07D498/08
CPC classification number: C07D403/14 , A61K31/505 , A61K31/506 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/10 , C07D491/107 , C07D498/08
Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
2.发明授权Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment 有权取代的环丙基化合物，含有这些化合物的组合物和治疗方法公开(公告)号：US09006228B2
公开(公告)日：2015-04-14
申请号：US14126685
申请日：2012-06-11
Applicant: Michael Miller , Andrew Stamford , Kallol Basu , Harold B. Wood , Duane DeMong , Wanying Sun , Joie Garfunkle , Christopher Moyes , Zhiyong Hu , Ping Liu , Scott D. Edmondson , Xing Dai , Byron Gabriel DuBois
Inventor： Michael Miller , Andrew Stamford , Kallol Basu , Harold B. Wood , Duane DeMong , Wanying Sun , Joie Garfunkle , Christopher Moyes , Zhiyong Hu , Ping Liu , Scott D. Edmondson , Xing Dai , Byron Gabriel DuBois
IPC: C07D417/14 , C07D211/24 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D211/22
CPC classification number: C07D211/24 , C07D211/22 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14
Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
Abstract translation: 公开了取代的式I的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病症。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法。
-
公开(公告)号：US09718818B2
公开(公告)日：2017-08-01
申请号：US14912761
申请日：2014-08-18
Applicant: MERCK SHARP & DOHME CORP. , Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
Inventor： Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
IPC: A61K31/44 , C07D471/04 , C07D498/04 , C07D519/00 , C07D487/04
CPC classification number: C07D471/04 , C07D487/04 , C07D498/04 , C07D519/00
Abstract: The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
公开(公告)号：US20160200722A1
公开(公告)日：2016-07-14
申请号：US14912761
申请日：2014-08-18
Applicant: Duane DEMONG , Thomas J. GRESHOCK , Ronald K. CHANG , Xing DAI , Hong LIU , John A. MCCAULEY , Wei LI , Kallol BASU , Jack D. SCOTT , Michael MILLER , MERCK SHARP & DOHME CORP.
Inventor： Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
IPC: C07D471/04 , C07D498/04 , C07D519/00
CPC classification number: C07D471/04 , C07D487/04 , C07D498/04 , C07D519/00
Abstract: The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Abstract translation: 本发明涉及作为LRRK2激酶的有效抑制剂并且可用于治疗或预防涉及LRRK2激酶的疾病（例如帕金森病）的唑烷化合物。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及LRRK-2激酶的疾病中的用途。
-
Patent Agency Ranking
公开(公告)号：US20120028975A1
公开(公告)日：2012-02-02
申请号：US13262990
申请日：2010-04-05
Applicant: Ginny D. Ho , Elizabeth M. Smith , Eugenia Y. Kiselgof , Kallol Basu , Zheng Tan , Brian McKittrick , Deen Tulshian
Inventor： Ginny D. Ho , Elizabeth M. Smith , Eugenia Y. Kiselgof , Kallol Basu , Zheng Tan , Brian McKittrick , Deen Tulshian
IPC: A61K31/437 , A61K31/5377 , A61P25/18 , A61P3/00 , A61P25/28 , A61P25/24 , A61P3/04 , A61P3/10 , C07D471/04 , A61P25/00
CPC classification number: C07D471/04
Abstract: The present invention relates to substituted triazolopyridines and analogs thereof, the use of the compounds as phosphodiesterase 10 (PDE10) inhibitors for the treatment of PDE10-modulated disorders, to pharmaceutical compositions comprising the compounds.
Abstract translation: 本发明涉及取代的三唑并吡啶类及其类似物，该化合物作为磷酸二酯酶10（PDE10）抑制剂用于治疗PDE10调节的病症的药物组合物用于包含该化合物的药物组合物。
-
公开(公告)号：US20160009689A1
公开(公告)日：2016-01-14
申请号：US14772295
申请日：2014-02-27
Applicant: Michael MILLER , Kallol BASU , Duane DEMONG , Jack SCOTT , Wei LI , Andrew STAMFORD , Marc POIRIER , Paul TEMPEST , MERCK SHARP & DOHME CORP.
Inventor： Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Wei Li , Andrew Stamford , Marc Poirer , Paul Tempest
IPC: C07D403/04 , C07D413/14 , C07D401/14 , C07D471/10 , C07D491/107 , C07D498/10 , C07D487/10 , C07D405/14 , C07D498/04 , C07D487/04 , C07D409/14 , C07D403/14 , C07D498/08
CPC classification number: C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/107 , C07D498/04 , C07D498/08 , C07D498/10
Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
7.发明申请SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT 有权取代的环丙基化合物，包含这些化合物的组合物和处理方法公开(公告)号：US20140128368A1
公开(公告)日：2014-05-08
申请号：US14126685
申请日：2012-06-11
Applicant: Michael Miller , Andrew Stamford , Kallol Basu , Harold B. Wood , Duane DeMong , Wanying Sun , Joie Garfunkle , Christopher Moyes , Zhiyong Hu , Ping Liu , Scott D. Edmondson , Xing Dai , Byron Gabriel DuBois
Inventor： Michael Miller , Andrew Stamford , Kallol Basu , Harold B. Wood , Duane DeMong , Wanying Sun , Joie Garfunkle , Christopher Moyes , Zhiyong Hu , Ping Liu , Scott D. Edmondson , Xing Dai , Byron Gabriel DuBois
IPC: C07D417/14 , C07D211/24 , C07D405/14 , C07D413/04 , C07D413/14 , C07D401/14 , C07D401/04
CPC classification number: C07D211/24 , C07D211/22 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14
Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
Abstract translation: 公开了取代的式I的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法。
-
公开(公告)号：US08685967B2
公开(公告)日：2014-04-01
申请号：US13262990
申请日：2010-04-05
Applicant: Ginny D. Ho , Elizabeth M. Smith , Eugenia Y. Kiselgof , Kallol Basu , Zheng Tan , Brian McKittrick , Deen Tulshian
Inventor： Ginny D. Ho , Elizabeth M. Smith , Eugenia Y. Kiselgof , Kallol Basu , Zheng Tan , Brian McKittrick , Deen Tulshian
IPC: A61K31/437 , A61K31/5377 , A61P25/18 , A61P3/00 , A61P25/28 , A61P25/24 , A61P3/04 , A61P3/10 , C07D471/04 , A61P25/00
CPC classification number: C07D471/04
Abstract: The present invention relates to substituted triazolopyridines and analogs thereof, the use of the compounds as phosphodiesterase 10 (PDE10) inhibitors for the treatment of PDE10-modulated disorders, to pharmaceutical compositions comprising the compounds.
Abstract translation: 本发明涉及取代的三唑并吡啶类及其类似物，该化合物作为磷酸二酯酶10（PDE10）抑制剂用于治疗PDE10调节的病症的药物组合物用于包含该化合物的药物组合物。
-
公开(公告)号：US20160009681A1
公开(公告)日：2016-01-14
申请号：US14772525
申请日：2014-02-27
Applicant: Michael MILLER , Kallol BASU , Duane MONG , Jack SCOTT , Hong LIU , Xing DAI , Andrew STAMFORD , Marc POIRIER , Paul TEMPEST , MERCK SHARP & DOHME CORP.
Inventor： Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Hong Liu , Xing Dai , Andrew Stamford , Marc Poirier , Paul Tempest
IPC: C07D401/04 , C07D498/08 , C07D401/14 , C07D495/08 , C07D498/04 , C07D487/04 , C07D413/14 , C07D405/14 , C07D417/14
CPC classification number: C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D491/08 , C07D495/08 , C07D498/04 , C07D498/08
Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
Abstract translation: 本发明涉及作为LRRK2激酶的有效抑制剂的吲唑化合物，可用于治疗或预防其中涉及LRRK2激酶的疾病，例如帕金森病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及LRRK2激酶的疾病中的用途。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.048 seconds)
